Cargando…

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

BACKGROUND: Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need is mainly due to the heterogeneity underlying both the mec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaminska, Kamila, Akrap, Nina, Staaf, Johan, Alves, Carla L., Ehinger, Anna, Ebbesson, Anna, Hedenfalk, Ingrid, Beumers, Lukas, Veerla, Srinivas, Harbst, Katja, Ehmsen, Sidse, Borgquist, Signe, Borg, Åke, Pérez-Fidalgo, Alejandro, Ditzel, Henrik J., Bosch, Ana, Honeth, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893923/ https://www.ncbi.nlm.nih.gov/pubmed/33602273 http://dx.doi.org/10.1186/s13058-021-01402-1

Ejemplares similares

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Alves, Carla L., et al.
Publicado: (2021)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer
por: Skov, Natascha, et al.
Publicado: (2022)

Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial
por: Feldt, Maria, et al.
Publicado: (2015)

How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast Cancer
por: Saghir, Hani, et al.
Publicado: (2022)

Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2022)

Laser capture microdissection (LCM) and whole genome amplification (WGA) of DNA from normal breast tissue --- optimization for genome wide array analyses
por: Aaltonen, Kristina E, et al.
Publicado: (2011)

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination
por: Ehmsen, Sidse, et al.
Publicado: (2022)

Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2021)

Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida, Monica, et al.
Publicado: (2020)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

SRIQ clustering: A fusion of Random Forest, QT clustering, and KNN concepts
por: Karlström, Jacob, et al.
Publicado: (2022)

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer
por: Kodahl, Annette R., et al.
Publicado: (2018)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response
por: Martín de la Fuente, Laura, et al.
Publicado: (2018)

Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex
por: Giessrigl, B, et al.
Publicado: (2013)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma
por: Arildsen, Nicolai Skovbjerg, et al.
Publicado: (2017)

SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
por: Bååth, Maria, et al.
Publicado: (2020)

Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
por: Veerla, Srinivas, et al.
Publicado: (2023)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

DNA methylation subgroups in melanoma are associated with proliferative and immunological processes
por: Lauss, Martin, et al.
Publicado: (2015)

Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer
por: Staaf, Johan, et al.
Publicado: (2011)

GOBO: Gene Expression-Based Outcome for Breast Cancer Online
por: Ringnér, Markus, et al.
Publicado: (2011)

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer
por: Alves, Carla L., et al.
Publicado: (2018)

Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series
por: Vallon-Christersson, Johan, et al.
Publicado: (2019)

The Dictator
Publicado: (1906)

Distinct Gene Expression Signatures in Lynch Syndrome and Familial Colorectal Cancer Type X
por: Dominguez-Valentin, Mev, et al.
Publicado: (2013)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Oestradiol measurement during fulvestrant treatment for breast cancer
por: Owen, Laura J., et al.
Publicado: (2019)

Abemaciclib/fulvestrant: Leucopenia and Covid-19: case report
Publicado: (2020)

Fulvestrant-Big Mac Index: Defining Inequality in Oncology
por: O'Reilly, David, et al.
Publicado: (2021)

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
por: Lindeman, Geoffrey J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n7hj40ukeqrvsfuu64h2oh27h4